Pharmacoeconomics study of rosuvastatin single daily dose versus alternate day dosing in hyperlipidemia patients

Mounika Vasa; Jabbala Kumar Raja; Madhukar Rao Polasani; Anurag Yadav

doi:10.5455/njppp.2023.13.06300202220092022

2024, Vol: 14, Issue: 12

14 / 12Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form

« Previous Article

Original Research
Online Published: 30 Sep 2022

Natl J Physiol Pharm Pharmacol. 2023; 13(5): 931-934

doi: 10.5455/njppp.2023.13.06300202220092022

Pharmacoeconomics study of rosuvastatin single daily dose versus alternate day dosing in hyperlipidemia patients

Mounika Vasa, Jabbala Kumar Raja, Madhukar Rao Polasani, Anurag Yadav.

Abstract
Background: In country like India, therapy with rosuvastatin recommended dose may cost between Rs. 400.00 and Rs. 800.00/month. The lower and middle income groups of Indian society are rapidly becoming major sufferers of cardiovascular disease, among all non-communicable diseases, the economic burden of rosuvastatin therapy may be substantial for this large section of population.

Aims and Objectives: The aim of the study was to study the cost-effectiveness of rosuvastatin on alternate day versus daily dosing regimen in hyperlipidemia patients.

Materials and Methods: The research was carried out at MNR Medical College and Hospital’s department of pharmacology in association with general medicine. According to the inclusion criteria, 50 patients aged 30–60 years of both sexes were included in this prospective open label trial. The research lasted 6 weeks. All the participants were included in study after obtaining the informed consent and approval of the Institutional Ethics Committee was obtained before enrolment of participants. All patient data were obtained using a pre-designed proforma and put into an excel spreadsheet.

Results: A total of 42 patients are included with 16 females (38%) and 26 men (62%). Cost of daily rosuvastatin for 6 weeks is Rs. 1087.80 (yearly daily dosing expenses 9453.50%) accounting for mean reduction of LDL-cholesterol (LDL-C) of 33.50% and for alternate day rosuvastatin for 6 weeks is 543.90% (yearly alternate day dosing expense 4713.80%) accounting for mean reduction of LDL-C of 31%.

Conclusion: Treatment with alternate day dose of rosuvastatin is comparably cost-effective when compared to currently practicing daily dose rosuvastatin therapy.

Key words: Rosuvastatin; Lipid; Pharmacoeconomics; Socio Economic Status; Coronary Vascular Disease

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Mounika Vasa Articles by Jabbala Kumar Raja Articles by Madhukar Rao Polasani Articles by Anurag Yadav
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Vasa M, Raja JK, Polasani MR, Yadav A. Pharmacoeconomics study of rosuvastatin single daily dose versus alternate day dosing in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol. 2023; 13(5): 931-934. doi:10.5455/njppp.2023.13.06300202220092022

Web Style

Vasa M, Raja JK, Polasani MR, Yadav A. Pharmacoeconomics study of rosuvastatin single daily dose versus alternate day dosing in hyperlipidemia patients. https://www.njppp.com/?mno=63464 [Access: January 17, 2025]. doi:10.5455/njppp.2023.13.06300202220092022

AMA (American Medical Association) Style

Vasa M, Raja JK, Polasani MR, Yadav A. Pharmacoeconomics study of rosuvastatin single daily dose versus alternate day dosing in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol. 2023; 13(5): 931-934. doi:10.5455/njppp.2023.13.06300202220092022

Vancouver/ICMJE Style

Vasa M, Raja JK, Polasani MR, Yadav A. Pharmacoeconomics study of rosuvastatin single daily dose versus alternate day dosing in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol. (2023), [cited January 17, 2025]; 13(5): 931-934. doi:10.5455/njppp.2023.13.06300202220092022

Harvard Style

Vasa, M., Raja, . J. K., Polasani, . M. R. & Yadav, . A. (2023) Pharmacoeconomics study of rosuvastatin single daily dose versus alternate day dosing in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol, 13 (5), 931-934. doi:10.5455/njppp.2023.13.06300202220092022

Turabian Style

Vasa, Mounika, Jabbala Kumar Raja, Madhukar Rao Polasani, and Anurag Yadav. 2023. Pharmacoeconomics study of rosuvastatin single daily dose versus alternate day dosing in hyperlipidemia patients. National Journal of Physiology, Pharmacy and Pharmacology, 13 (5), 931-934. doi:10.5455/njppp.2023.13.06300202220092022

Chicago Style

Vasa, Mounika, Jabbala Kumar Raja, Madhukar Rao Polasani, and Anurag Yadav. "Pharmacoeconomics study of rosuvastatin single daily dose versus alternate day dosing in hyperlipidemia patients." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 931-934. doi:10.5455/njppp.2023.13.06300202220092022

MLA (The Modern Language Association) Style

Vasa, Mounika, Jabbala Kumar Raja, Madhukar Rao Polasani, and Anurag Yadav. "Pharmacoeconomics study of rosuvastatin single daily dose versus alternate day dosing in hyperlipidemia patients." National Journal of Physiology, Pharmacy and Pharmacology 13.5 (2023), 931-934. Print. doi:10.5455/njppp.2023.13.06300202220092022

APA (American Psychological Association) Style

Vasa, M., Raja, . J. K., Polasani, . M. R. & Yadav, . A. (2023) Pharmacoeconomics study of rosuvastatin single daily dose versus alternate day dosing in hyperlipidemia patients. National Journal of Physiology, Pharmacy and Pharmacology, 13 (5), 931-934. doi:10.5455/njppp.2023.13.06300202220092022

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Digital Archiving & Preservation Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article